文献速递肝病

利福昔明在严重肝硬化和腹水患者中的效果:一项随机双盲安慰剂对照试验

Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial.
PubMed 文献 · J Hepatol · 2025-07-11

在法国17个中心进行的随机双盲安慰剂对照试验中,严重肝硬化伴2级或3级腹水且腹水蛋白<15 g/L的患者随机接受利福昔明550 mg或安慰剂每日两次治疗12个月,作为自发性细菌性腹膜炎的一级预防。利福昔明未改善12个月、6个月或3个月生存率,也未降低肝硬化并发症发生率。在依从患者的符合方案分析中,利福昔明组12个月肝脏相关事件累积发生率较低。

要点

  • 利福昔明未改善严重肝硬化伴腹水患者的12个月生存率(安慰剂组68.1% vs 利福昔明组56.6%,p=0.74)。
  • 利福昔明未降低肝硬化并发症(自发性细菌性腹膜炎、肝性脑病、消化道出血或肝肾综合征)的发生率。
  • 在坚持服药的符合方案人群中,利福昔明组12个月肝脏相关事件的累积发生率较低。

核心结论

  • 利福昔明对严重肝硬化和低腹水蛋白水平患者的12个月生存率或肝硬化并发症发生率无有益影响。
  • 提高依从性可能有助于减少肝脏相关并发症。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在法国17个中心进行。
  • 纳入严重肝硬化伴2级或3级腹水且腹水蛋白水平<15 g/L的患者。
  • 患者按1:1随机接受利福昔明550 mg或安慰剂每日两次,持续12个月,作为自发性细菌性腹膜炎的一级预防。
  • 2018年至2022年间筛查1957例肝硬化腹水患者,随机159例,改良意向治疗人群分析152例(安慰剂组80例,利福昔明组72例)。

主要发现

  • 利福昔明未改善12个月生存率(安慰剂组68.1%,95%CI 56.2-78.7 vs 利福昔明组56.6%,95%CI 43.5-67.8;p=0.74)。
  • 利福昔明未改善6个月生存率(安慰剂组71.1%,95%CI 59.5-80.0 vs 利福昔明组76.4%,95%CI 64.3-84.8)。
  • 利福昔明未改善3个月生存率(安慰剂组75.4%,95%CI 64.1-83.5 vs 利福昔明组82.6%,95%CI 71.4-89.7)。
  • 利福昔明未降低肝硬化并发症(自发性细菌性腹膜炎、肝性脑病、消化道出血或肝肾综合征)的发生率。
  • 在符合方案人群(127例坚持研究药物的患者)中,利福昔明组12个月肝脏相关事件的累积发生率较低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Evidence supporting primary prophylaxis of spontaneous bacterial peritonitis (SBP) is weak and the selection of quinolone-resistant bacteria is a concern. Herein, we present results from a randomized, double-blind, placebo (PBO)-controlled trial to assess whether rifaximin (RFX) has a beneficial effect on 12-month survival in patients with severe cirrhosis and ascites. METHODS: In this trial conducted at 17 French centers, patients with severe cirrhosis and grade 2 or 3 ascites and ascites protein level <15 g/L were randomized 1:1 to receive RFX 550 mg or PBO twice daily for 12 months, as primary prophylaxis for SBP. The primary endpoint was 12-month survival. Secondary endpoints were 3- and 6-month survival, incidence of complications of cirrhosis, and safety of RFX. RESULTS: Between 2018 and 2022, 1,957 patients with cirrhosis and ascites were screened, 159 were randomized, and 152 (80/72 PBO/RFX) were analyzed in the modified intention-to-treat population. RFX did not improve 12-month (PBO vs. RFX: 68.1%, 95% CI 56.2-78.7 vs. 56.6%, 95% CI 43.5-67.8; p = 0.74), 6-month (71.1%, 95% CI 59.5-80.0 vs. 76.4%, 95% CI 64.3-84.8) or 3-month (75.4%, 95% CI 64.1-83.5 vs. 82.6%, 95% CI 71.4-89.7) survival, or the incidence of liver complications (SBP, encephalopathy, gastrointestinal bleeding or hepatorenal syndrome). In the per-protocol population (127 patients adherent to the study drug), a lower 12-month cumulative incidence of liver-related events was observed in the RFX group. RFX was well tolerated throughout the study. CONCLUSIONS: RFX had no beneficial effect in terms of 12-month survival or incidence of complications of cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels. However, improved adherence may help reduce liver-related complications. IMPACT AND IMPLICATIONS: Selective gut decontamination using norfloxacin is the standard of care for secondary prophylaxis of spontaneous bacterial peritonitis (SBP). Evidence for primary prophylaxis of SBP is weaker, and fluoroquinolones have been associated with an increased risk of antimicrobial resistance. Rifaximin, a well-tolerated broad-spectrum antibiotic associated with a lower risk of antimicrobial resistance emergence, may be an alternative to norfloxacin. Our trial did not demonstrate an improvement in survival or liver complications (SBP, gastrointestinal bleeding, hepatic encephalopathy or hepatorenal syndrome) at 12 months with rifaximin as primary prophylaxis for SBP vs. placebo. However, in the subgroup of patients who adhered to rifaximin, liver complications decreased. Our study underlines the importance of treatment adherence in clinical trials to ensure accurate assessment of outcomes. CLINICAL TRIAL NUMBER: NCT03069131.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Thévenot T, Elkrief L, Bureau C, et al. Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled trial. J Hepatol. 2025. PMID: 40653111. doi:10.1016/j.jhep.2025.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。